Viral Vector– tag –
-
Cytiva’s ELEVECTA Cell Line Receives FDA AMT Designation, Pioneering Next-Gen AAV Manufacturing with 99% Host Cell DNA Reduction
BioPharma BoardRoom USA Overview Cytiva, a Danaher company, has secured FDA Advanced Manufacturing Technology (AMT) designation for its ELEVECTA transient cell line, designed for adeno-associated virus (AAV) manufacturing. This pioneerin... -
Aldevron and Minaris Renew Lentiviral Plasmid Agreement, Bolstering Critical Supply for Advanced Cell and Gene Therapies
BioBuzz USA Overview Aldevron and Minaris have renewed their lentiviral plasmid licensing agreement, significantly expanding access to scalable plasmid solutions essential for advanced cell and gene therapy (CGT) developers. This collabo... -
CDMO Sector Sees Strategic Expansions: Andelyn Biosciences Launches LVV Platform, Made Scientific Partners with RoosterBio
DCAT Value Chain Insights USA Overview The biopharmaceutical contract development and manufacturing (CDMO) sector is experiencing significant strategic advancements, with Andelyn Biosciences unveiling its 'LVV curator platform' for stand... -
Advanced PCR Strategies Critical for Precision and Safety in Cell and Gene Therapy Development
Biocompare USA Overview Polymerase Chain Reaction (PCR) technologies are pivotal across the entire lifecycle of cell and gene therapy (CGT) product development, from early gene target validation to comprehensive quality and safety assess... -
Contract Organizations’ Pivotal Role in Lentiviral Manufacturing Accelerates Gene Therapy Commercialization
MAI CDMO Global Overview This article highlights the essential role of Contract Development and Manufacturing Organizations (CDMOs) in lentiviral vector manufacturing, crucial for gene and cell therapies like CAR-T. Lentiviral vector pro... -
Viral Vector Manufacturing Market Projected to Reach USD 12.84 Billion by 2036: Driven by Gene Therapy Advances and CDMO Role
OpenPR Global Overview This article provides an overview of a market research report distributed by OpenPR. The report forecasts that the global viral vector manufacturing market will reach USD 12.84 billion by 2036, driven by the increa... -
The Modern CDMO: A Strategic Blueprint for Pharmaceutical Leaders in a Complex Era
Agnopharma Global Overview This guide outlines the evolution of CDMOs from traditional CMOs, emphasizing their indispensable role in contemporary drug development. Modern CDMOs offer integrated solutions from process development to comme... -
OpenBind Launches First Open Dataset and AI Model to Enhance Drug-Target Interaction Prediction, Applied to EV-A71 Virus
University of Oxford UK Overview Researchers at the University of Oxford, as part of the OpenBind consortium, have released the first open dataset and predictive AI model specifically designed for drug discovery. This dataset comprises d... -
NIH-Funded Research Achieves Breakthrough in Shrinking CRISPR Systems for Enhanced In Vivo Precision Delivery
European AIDS Treatment Group (EATG) News USA Overview NIH-funded research has successfully developed miniaturized CRISPR-Cas gene editing systems, overcoming a significant hurdle in in vivo delivery for traditional larger systems. This ... -
Genprex Collaborators Report Positive Preclinical Data for Diabetes Gene Therapy at ASGCT 2026, Showing Alpha-to-Beta Cell Reprogramming
PR Newswire USA Overview Genprex's collaborators presented positive preclinical data at ASGCT 2026 for GPX-002, a gene therapy candidate for Type 2 Diabetes (T2D). The therapy, which delivers Pdx1/MafA genes to the pancreas via an AAV ve...
